Group items tagged

Leyla Hannbeck, chief executive of the Association of Independent Multiple Pharmacies has said pharmacists have been "struggling to obtain the very basic, most common cold and flu medicine." She told the PA news agency that the shortage wasn't around "just the branded medicines" but "also simple things like throat lozenges, cough mixtures or pain killers - particularly the ones that are soluble." Stating that the sector was finding it very difficult these shortages she said "those people who are in charge of supporting us with it are denying it." "The demand has been high because this season we've seen higher cases of colds and flu and people are obviously trying very hard to look after themselves and making sure that they use the relevant products to manage the symptoms.

The Company Chemist Association (CCA) highlighted its concerns around the recruitment of pharmacists into Primary Care Networks as well as the need for additional investment. Commenting on the Ipsos survey findings, the Malcolm Harrison, the Chief executive of the CCA said: "We welcome the findings of the Ipsos survey, confirming that patients value the quality of service and advice community pharmacies routinely provide. "We are very concerned however that this cancer detection pilot, and all other pharmacy services, are at risk if the NHS is not prepared to inject urgently needed funding into the sector." He stated that without substantial investment, "we will see the continued erosion of the service pharmacies can provide." In addition to the need for critical additional funding the association is also calling on the NHS to pause the recruitment of pharmacists into GP surgeries. He said: "Patients are suffering because the demand for pharmacists in England is now significantly greater than that which the existing workforce can deliver."

A survey of over six thousands pharmacies has revealed that the community pharmacy sector is buckling under growing cost and capacity pressures. The survey conducted by the Pharmaceutical Services Negotiating Committee, which also involved two thousand community pharmacy confirms, rising costs, patient demand and medicine supply issues continue to grip the sector. PSNC's 2023 Pharmacy Pressures Survey, run as a follow up to the 2022 pressures survey, provides clear comparative data showing the worsening situation across the sector. Govt must act now The result of the survey indeed paints a bleak picture for community pharmacies and it is clear that without urgent action from government and the NHS this will only get worse: more community pharmacies will either be forced to reduce the number of services they provide or, in the worst-case scenario, will be left with no option but to close their doors for good. The PSNC has urged the government to act now "to save our pharmacies, before it is too late for patients, the public, and the rest of the NHS". "This year's survey clearly shows that community pharmacies are buckling under growing cost and capacity pressures," said PSNC Chief Executive Janet Morrison.

The Department of Health and Social Care (DHSC) has issued an alert to update healthcare professionals on the shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are used to treat type 2 diabetes. It has informed that the supply of the drugs continues to be limited, and is not expected to return to normal until at least the end of 2024. An increase in demand for these products for licensed and off-label indications is cited as the cause of the supply issues. "Rybelsus® (semaglutide) tablets are now available in sufficient quantities to support initiation of GLP1 RA treatment in people with type 2 diabetes (T2DM) in whom new initiation of GLP-1 RA therapy would be clinically appropriate," the DHSC's National Patient Safety Alert reads.

The General Pharmaceutical Council (GPhC) and the Chief Pharmaceutical Officer for England have written a letter to pharmacy professionals thanking them for providing the best possible services to patients and the public, despite experiencing high and sustained demands and pressures. GPhC Chief Executive Duncan Rudkin and CPhO David Webb indicated that there will be further challenges over the coming weeks and months due to the ongoing industrial action, and staff shortages due to sickness or caring responsibilities. They expressed concerned that increased pressure will have a significant and potentially prolonged impact on pharmacy teams both personally and professionally. Acknowledging that pharmacy professionals may have to make some difficult decisions as they deal with the pressures they face, the leaders have urged those working in pharmacy to use "your professional judgement to assess and mitigate risk, and to deliver safe and effective care for your patients within your scope of practice."

In a recent report released by the Company Chemists' Association (CCA), data from the NHS Pharmacy First service indicates a substantial uptake and positive impact on patient care just two months after its launch. The CCA's findings shed light on the service's efficacy in meeting patient needs and its potential to alleviate pressure on General Practices (GPs) within the NHS. According to the report, over 90,000 Pharmacy First consultations were conducted solely by CCA members within the initial two-month period. Impressively, 88 per cent of these consultations, totaling 81,627, were deemed eligible for NHS-funded care indicating a significant demand for the service among patients. In the first month, the data revealed that more than 90 per cent of eligible patients received necessary care directly through Pharmacy First, bypassing the need for further referral.

The Association of Independent Multiple Pharmacies (AIMp) has changed its name to the Independent Pharmacies Association (IPA). AIMp, now IPA, stated that rebranding was prompted by the demand from independent community pharmacists for an association that properly represents their interests. The membership of the Independent Pharmacies Association will not be restricted to pharmacy owners with multiple branches, as was the case with AIMp, but will be open to all independents, it announced today (Tuesday). It believes that the switch will "provide a clearer identity and afford a strong voice to the thousands of independent pharmacies in England and Wales." Furthermore, the IPA noted that it will not primarily function as an insurance organisation with membership attached, but it will be "fighting for and representing its members across all fronts."

Hospitals and healthcare providers across the UK have been notified about the shortage of an anti-inflammatory medicine caused by a manufacturing failure. The Department of Health and Social Care (DHSC) on Friday (3 May) issued a National Patient Safety Alert stating that Erelzi 50mg solution for injection in pre-filled pen will be out of stock from early May until mid-July 2024. "The supply issues have been caused by a manufacturing failure resulting in delays in production and the implementation of global allocations," it said. However, it noted that homecare providers (Alcura, Healthnet and Sciensus) have sufficient stock to supply existing patients until mid/late May 2024. Although Erelzi 50mg pre-filled syringes (PFS) are still available, they cannot support a full increase in demand, the DHSC warned.

The Professional Pharmacists Association (PDA) has demanded efforts to secure greater support and recognition for community pharmacists from governmental bodies. In its written evidence provided to the Health and Social Care select committee's pharmacy inquiry, the PDA raised concerns about the well-being of pharmacists, specifically for those who belong to minority ethnic groups and race and are subjected to bullying, harassment, and ill-treatment. The association highlighted issues in the workplace that impact pharmacists' health and well-being, including chronic understaffing, sub-standard working environments, an absence of protected training time, and experiences of racism, violence, and abuse. Parallel to the PDA's advocacy, the Royal Pharmaceutical Society (RPS) is intensifying calls for prioritising workforce wellbeing within the pharmacy domain. Stressing the pivotal role of workforce retention in addressing current challenges, RPS emphasises the need for robust support mechanisms and equitable access to mental health services.

The States of Guernsey have urged Islanders to plan ahead for their medication needs ahead of the upcoming Easter weekend. With a reduced number of pharmacies expected to be open during the holiday, residents are being asked to arrange for their repeat prescriptions well in advance. Alternatively, the government body announced that residents can opt to wait until after the Easter period if they already have an ample supply of medication at home. This proactive measure aims to provide support to pharmacies and their staff, particularly during a period where demand for healthcare services may be heightened.

NHS England has launched a cloud-based platform that links recently-retired consultants, who still hold a licence to practice, with secondary care providers who need additional help with their waiting lists. It has been developed to make it easier and more flexible for retired doctors to return to the health service as part of the Long Term Workforce Plan. NHS chief executive Amanda Pritchard in June 2023 announced the NHS Emeritus pilot scheme, which is expected to help reduce long waits for elective care. Initially, the scheme will run for a year across England, and if successful, it may be expanded to cover other work areas. Health Minister Andrew Stephenson commented: "Returning consultants will bring invaluable experience and knowledge, and the new digital platform will match highly-skilled consultants with the NHS trusts that require their expertise, providing high quality care and alleviating pressures on high demand areas.

Derriford Hospital is set to move its outpatient pharmacy to a bigger unit, which will be twice as big as the current size. The new pharmacy, due to open in Spring 2024, is located adjacent to the hospital's on-site Costa Coffee shop in the multistorey car park building. University Hospitals Plymouth NHS Trust said work is ongoing on the new 155 square metres pharmacy, but measures such as covered seating has been implemented. Additionally, the pharmacy's opening times would be extended during the weekends to benefit patients who are unable to attend during the week, the Trust said, noting that demand for its services has grown by 25 per cent. Kandarp Thakkar, Chief Pharmacist & Clinical Director of Medicines Optimisation, said the pharmacy serves thousands of outpatient appointments each week.

Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy software supplier Cegedim Rx. The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said. Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5). Tristan de Foucher, head of European operations for Cegedim Group, said: "Adam has been a force of nature in this business for the past 10 years. Under his leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community pharmacy." Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on both care delivery and technology implementation.

In a significant move to enhance the working conditions of over 50,000 postgraduate doctors in the National Health Service, NHS England has unveiled a series of measures aimed at providing greater choice and opportunities to the new entrants in the medical profession. With flexible rotas, reducing payroll errors, and easing the financial burden of course fees, the NHS has taken steps to address the issues faced by junior doctors in order to support their well-being. In recent announcement, 83 per cent of senior doctors and dentists accepted the government's pay offer. Alongside the junior doctors who still fighting for fair pay and recognition, the senior medical professionals demanded that the authorities help them tackle issues pertaining underfunding and overworking in the NHS. Junior doctors in training also often face challenges with frequent moves between trusts, leading to short notice changes in work schedules and duplicated inductions when transitioning to new hospitals. As a measure taken by the health serivces, the committee aims to review the minimum legal requirements for statutory and mandatory training, potentially halving the time burden for such training and allowing doctors to spend more time caring for patients as part of the long-term workforce plan.

A recent UNISON survey has unearthed disturbing findings regarding the prevalence of sexual harassment among NHS staff across the UK. With data collected from over 12,000 healthcare workers, the survey sheds light on the challenges faced by frontline workers in their workplace environments. Approximately 10 per cent of healthcare professionals reported instances of sexual harassment during their tenure, with nearly 29 per cent of those experiencing harassment also reporting incidents of sexual assault. Shockingly, 50 per cent of respondents reported being leered at or subjected to suggestive gestures, while a quarter faced unwelcome sexual advances or demands for favors. The most common complaint, voiced by 61 per cent of those affected, was the experience of unwanted crude banter or jokes in the workplace.

In a bid to bolster the educational experience for undergraduate pharmacy students across London, Kingston University has embarked on a groundbreaking project in collaboration with University College London and King's College London. This initiative, fueled by a substantial £1.5 million investment from National Health Services England (NHSE), aims to elevate the quality and consistency of pharmacy placements throughout the capital for new pharmacy entrants. The project is designed to address the evolving standards set forth by the General Pharmaceutical Council (GphC), ensuring that newly-trained pharmacists are well-prepared to meet the demands of their profession. By standardizing and expanding pharmacy placements, the three universities seek to provide students with a comprehensive and diverse range of "experiential learning opportunities".

Leading health and beauty retailer Superdrug on Monday announced that it has selected on-demand delivery network Gophr to provide its pharmacy delivery service, following a rigorous Request for Information (RFI) process. This means Gophr will be responsible for delivering prescriptions across the UK to people who choose Superdrug to provide their medication. Superdrug's decision to choose Gophr was influenced significantly by the latter's strong Standard Operating Procedures (SOP), its adept ability to track and trace all home deliveries digitally from store to door, and its commitment to offering a best-in-class doorstep experience. According to the retailer, multiple layers of protection are implemented during delivery to uphold standards, ensuring that prescription medicines are handed directly to the intended recipients. Graham Smith, strategic account director at Gophr, highlighted the growing importance of pharmaceutical delivery, especially as pharmacists are now able to provide even more services under Pharmacy First scheme.

The Department of Health and Social Care (DHSC) published a notification regarding the shortage of Guanfacine 2mg and 3mg modified-release tablets has raised concerns within the healthcare community. This critical medicine supply notification, issued on March 28th, projects the unavailability of these tablets until the week commencing May 6, 2024. Guanfacine tablets, commonly prescribed to alleviate symptoms of hyperactivity and impulsivity while enhancing attention and concentration, play a vital role in managing conditions like attention deficit hyperactivity disorder (ADHD). However, the scarcity of these specific strengths poses challenges for patients reliant on this medication. Last year, several countries across the globe experienced shortages of medications for the treatment of attention deficit hyperactivity disorder (ADHD)including the UK, the US and Australia. Community Pharmacy England (CPE) has cautioned that while alternative strengths of Guanfacine remain accessible, they may not adequately meet the heightened demand, potentially resulting in treatment interruptions for patients.

People in the UK are increasingly relying on community pharmacies for health advice and support as they are unable to access their general practitioner (GP). According to a recent report by the Liberal Democrats, there was a significant increase in the number of patients waiting four weeks or more to see a GP in England last year, rising from 12.8 million in 2022 to 17.6 million. Responding to this research report, the Royal College of General Practitioners (RCGP) highlighted that GPs are also struggling to meet the increasing demand for their services due to severe staff shortages. Dr. Victoria Tzortziou-Brown, Vice Chair of the RCGP, stated that the average number of patients each GP is responsible for has increased by 158 compared to five years ago. Although she acknowledged that many patients are forced to wait for weeks to see their GP, she said that doctors too are grappling with "unmanageable and unsustainable workloads" and "we can't keep doing more with less."

Covid-19 vaccine maker Novavax on Wednesday said it expects revenue this year to be flat or lower as it works to improve its commercial performance and pick up market share from much larger rivals, Pfizer and Moderna. The company posted a larger-than-expected fourth-quarter loss as revenue lagged analysts' estimates. Chief executive John Jacobs said Novavax claimed just a low-single-digit percentage market share in the US during the most recent vaccination campaign, as demand for Covid vaccines was smaller than hoped and the company got its protein-based shot to market later than its messenger RNA-based rivals. "We were disappointed with that US performance," Jacobs said in an interview. He said the company's sales force was not targeted enough toward retail pharmacy chains, and that its 5-dose vials were not as convenient for use as rivals' pre-filled syringes.